The Cancer Genomics and Tumor Immunotherapy Symposium: A Clinical Perspective is a key educational event, jointly hosted by the Cancer Genomics Program (CGP) and the Tumor Immunotherapy Program (TIP) at the Princess Margaret Cancer Centre. The objective of this Symposium is to provide a clinical and translational perspective on cancer genomics and tumor immunotherapy by highlighting emerging therapies and technologies as they apply to precision cancer medicine at the point of care. Participants will learn about new research on mechanisms of resistance and response, emerging therapies and technologies aimed at increasing the personalized approach to treatment, and genomic applications in the clinic.

This one-day symposium will be held at the MaRS Discovery District in downtown Toronto:

MaRS Discovery District 
101 College Street, 
Toronto, ON  
M5G 1L7


Confirmed speakers include:

Trey Ideker, PhD, University of California San Diego

Benjamin Haibe-Kains, PhD, Princess Margaret Cancer Centre

Anna Goldenberg, PhD, SickKids

Jennifer Knox, MD, Princess Margaret Cancer Centre 

Daniel Renouf, MD, British Columbia Cancer Agency

Prasad Adusumilli, MD, Memorial Sloan Kettering Cancer Center

Bertrand Routy, MD, PhD, Centre Hospitalier de l'Université de Montréal

Michele Ardolino, PhD, The Ottawa Hospital

Mary Philip, MD, PhD, Vanderbilt University Medical Center


Target Audience for the 2019 Cancer Genomics and Tumor Immunotherapy Symposium:

  • Oncologists: Medical, Radiation, Surgical
  • Pathologists
  • Clinical Geneticists
  • Genetic Counselors
  • Laboratory Directors
  • Laboratory Technicians
  • Oncology Nurses
  • Bioinformaticians
  • Basic and Translational Scientists
  • Basic, Translational and Clinical Trainees
  • Pharmaceutical Representatives


Topics to be discussed in a presentation or panel include:

  • Network Medicine in Precision Oncology
  • PharmacoDB and Data Science in Cancer Genomics
  • AI and Cancer Genomics (Drug Response Prediction)
  • CAR-T Therapy in Solid Tumors
  • Microbiome in Cancer
  • The Role of PD-1 in NK-mediated tumor attack
  • Epigenetic and molecular programs regulating T cell dysfunction and reprogramming in cancer